Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma.
about
Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy.Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma.Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention.Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation.Lenalidomide in the treatment of young patients with multiple myeloma: from induction to consolidation/maintenance therapyHematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma.Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in OncologyInternational myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).Advances in mobilization for the optimization of autologous stem cell transplantation.Peripheral blood stem cell mobilization tactics.Current multiple myeloma treatment strategies with novel agents: a European perspectiveHow best to use new therapies in multiple myeloma.High rate of stem cell mobilization failure after thalidomide and oral cyclophosphamide induction therapy for multiple myeloma.The Belgian 2010 consensus recommendations for the treatment of multiple myeloma.Mobilization of hematopoietic stem cells into the peripheral blood.Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice.Novel immunomodulatory compounds in multiple myeloma.The evolving role of plerixafor in hematopoietic progenitor cell mobilization.Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin's lymphoma and multiple myeloma.Chemomobilization with high-dose etoposide and G-CSF results in effective and safe stem cell collection in heavily pretreated lymphoma patients: report from a single institution study and review.Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean mulImpact of lenalidomide-based induction therapy on the mobilization of CD34(+) cells, blood graft cellular composition, and post-transplant recovery in myeloma patients: a prospective multicenter study.Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation.A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma.Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.Management of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma.Successful autologous stem cell collection with filgrastim and plerixafor after long-term lenalidomide therapy for multiple myeloma.Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study.Mobilization and transplantation patterns of autologous hematopoietic stem cells in multiple myeloma and non-Hodgkin lymphoma.Plerixafor for autologous CD34 cell mobilization.Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo OsseoMultiple myeloma: biology, standard therapy, and transplant therapy.Lenalidomide in multiple myeloma.Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
P2860
Q33411277-5B400D96-D8A2-4B29-85D7-886C2B360B55Q34038564-083C73A2-2BF4-4FE9-ABBC-8D0E6F79A9D1Q34490998-544C06B1-58BB-4D38-BFD6-0245EFE1203BQ34604658-63081337-73E9-4AB4-8A9B-5D5E42D9E6CBQ35157385-C19C82FE-4533-4B83-9C5C-0075C05A42EBQ35994520-4F823982-AE27-47F8-AA75-935BF0CAF219Q36104325-93ACC3D7-2D63-4EF5-B238-C4DC3D2CAB86Q36428104-94E7A7DC-B7CB-4D86-96A9-93E24AB8F8B9Q36570256-BF28C2A7-C6C0-4BDA-919E-346F6B661783Q36765107-77B6E6ED-C413-41EF-B355-9D38948BD25AQ36963203-75923AE8-80CF-4441-AF37-6AEE06D85239Q37530452-62E4004F-915D-417F-9B93-DF720F95B8A8Q37551715-3CEFCF1F-EB0B-4A5B-AF00-CBA5C272FD5EQ37649251-EBC91C7D-50E4-4567-9D58-7A631E5DD027Q37677935-4F23A935-8919-4F28-A742-B13ABBB20556Q37723000-849C3A4C-7165-49B0-833D-6FAA2A16625AQ37766453-51E6F235-D9A8-4051-82AE-A8902E461D1AQ37800884-3A02AB13-5063-49C4-8A3B-5641D7641483Q37810088-C11EB325-9201-4FF6-B85A-9FEA6C33E80BQ37842346-178C158D-CB6D-477E-AB57-582C4DDEC760Q37991783-4899A8EF-672F-4199-A8B8-82380DB445A4Q38069614-16A13FEB-8698-4296-9721-457B5ED83E92Q38077807-0424B13D-A5A1-4DC0-8857-B8B2A813498CQ38160461-D05ACE2E-1DF6-4796-8783-3AB80AA02C0CQ38176669-01D2A59F-E00E-46C8-B68A-9F409836E9E8Q38200909-F7A19837-151D-4C63-AFBD-B876C924B70FQ38418369-062F05A7-6A9E-4B04-88EC-C61AC7F72D30Q38691698-EF7530F2-4F59-48B2-A0E7-A851506BDAA6Q38757483-3AD198FE-4F21-4762-BFAA-97864565F5C4Q38771752-CBB70BF9-6104-4C69-8887-F0BA813BF19FQ38859426-8F83E5F6-F139-4E02-837C-BDFEFEDD7E79Q38970595-FC326ADF-BD8A-422F-A0BD-1C9D92866725Q39478021-1A84537C-4FC3-42AB-B136-B89EF61A6E88Q41003137-037521EF-5210-4D96-A986-C31181DC01C4Q41694417-1CD8F6FE-D746-4DFA-B0BC-5B4A77C1BB44Q42204448-8584E0A2-1434-4451-BC97-87BC730DA568Q42592824-DB682EFE-CD2F-40F7-8769-8463A68CC928Q42794048-3B850DB1-F02A-411E-949D-29C032CDC29EQ43247044-BEBD3600-51CC-482D-83DB-F0CEF4C25776Q44986060-F4C8E9D3-9924-48AD-B3AB-339F178ECCB3
P2860
Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Compromised stem cell mobiliza ...... with lenalidomide in myeloma.
@en
Compromised stem cell mobiliza ...... with lenalidomide in myeloma.
@nl
type
label
Compromised stem cell mobiliza ...... with lenalidomide in myeloma.
@en
Compromised stem cell mobiliza ...... with lenalidomide in myeloma.
@nl
prefLabel
Compromised stem cell mobiliza ...... with lenalidomide in myeloma.
@en
Compromised stem cell mobiliza ...... with lenalidomide in myeloma.
@nl
P2093
P356
P1433
P1476
Compromised stem cell mobiliza ...... y with lenalidomide in myeloma
@en
P2093
A K Stewart
A S Torloni
C Ehlenbeck
H Paripati
J Boesiger
P L Bergsagel
P2888
P304
P356
10.1038/SJ.LEU.2405100
P577
2008-01-24T00:00:00Z